Beijing Tong Ren Tang Chinese Medicine Company Limited EBIT

As of the most recent data (June 2026), BJTRF shows a EBIT of $540M. That compares with $580M in the prior-year period — down 7.5% year over year. That is below the sector sector average of $2.5T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BJTRF's EBIT is now $540M (was $580M) — a 7.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Beijing Tong Ren Tang Chinese Medicine Company Limited is outperforming or lagging.

The its sector sector average EBIT is about $2.5T. Beijing Tong Ren Tang Chinese Medicine Company Limited is at $540M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how BJTRF stacks up against individual peers as well.

Tracking BJTRF's ebit over time shows whether Beijing Tong Ren Tang Chinese Medicine Company Limited is scaling, shrinking, or reshaping that part of the business. The current reading is $540M That compares with $580M in the prior-year period — down 7.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Beijing Tong Ren Tang Chinese Medicine Company Limited's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $540M) with ownership activity and broader fundamentals.